Clinical features and laboratory findings of human parvovirus B19 in human immunodeficiency virus-infected patients

Pereira, Renata Freire Alves; Garcia, Rita de Cássia Nasser Cubel; Azevedo, Kátia Martins Lopes de; Setúbal, Sérgio; Siqueira, Marilda Agudo Mendonça Teixeira de; Oliveira, Solange Artimos de

doi:10.1590/0074-02760130312

Cited by 12 publications

(10 citation statements)

References 27 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However with the introduction of HAART and its impact on restoring immune response, recent studies have shown reduction in anemia related B19 infection [Ferry et al, ; Pereira et al, ]. Our study also demonstrated that persistent B19 infection causing anemia is a rare finding in our cohort of HIV patients.…”

Section: Discussionsupporting

confidence: 67%

“…Anemia related B19 virus is very important in HIV infected subjects, because it is a treatable cause of anemia in this population with blood transfusions and high intravenous doses of human immunoglobulin [Frickhofen et al, ]. However, with the introduction of highly active antiretroviral treatment (HAART), recent studies have shown low number of cases with anemia caused by B19 in HIV infected patients [de Azevedo et al, ; Pereira et al, ]. Several studies have reported that almost 30% of HIV infected patients have no IgG antibodies against B19 and are at risk of developing B19 infection, persistent viremia and chronic anemia [Azevedo et al, ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Frequency and genotype of human parvovirus B19 among Iranian patients infected with HIV

et al. 2015

View full text Add to dashboard Cite

The human parvovirus B19 (B19) usually causes a subclinical infection in immunocompetent individuals. Whereas immunocompromised individuals such as patients infected with HIV are at risk of persistent anemia due to B19 infection. Only few studies have been carried out on distribution and molecular epidemiology of B19 in Iran. We aimed to determine the frequency and genotype of B19 among Iranian patients infected with HIV. We conducted a survey on 99 HIV patients and 64 healthy controls. IgG and IgM antibodies against B19 were detected by ELISA and B19 DNA was assessed by nested PCR. PCR products were subjected to direct sequencing and classified after phylogenetic analysis. The prevalence of B19 immunoglobulin was 11.1% for IgG and 1% for IgM. B19 DNA was detected in 13.1% of cases. The prevalence of B19 IgG, IgM, and DNA in control group was 25%, 1.6%, and 9.4%, respectively. B19 IgG was significantly lower in HIV group than in normal controls. There was no significant difference regarding anemia between cases and controls. All sequenced B19 isolates belonged to genotype 1A with low genetic diversity. Our findings indicated that in the HAART era, the importance of B19 infections in HIV patients may be limited whereas persistent B19 viremia in the circulation of healthy controls raises a potential concern in blood donations.

show abstract

Section: Discussionsupporting

confidence: 67%

Section: Introductionmentioning

confidence: 99%

Frequency and genotype of human parvovirus B19 among Iranian patients infected with HIV

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Phylogenetic analysis revealed that two samples from unit 3 were clustered to genotype 1 and classified as genotype 1A. Genotype 1 is the most common in Brazil, with a frequency of 87.9% according to previous studies (Cubel Garcia et al, 2017;Di Paola et al, 2019;Figueiredo et al, 2019;Freitas et al, 2008;Pereira et al, 2014).…”

Section: Discussionmentioning

confidence: 80%

High prevalence of parvovirus B19 infection in patients with chronic kidney disease under hemodialysis: A multicenter study

Alves

Langella

Barbosa

et al. 2020

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Objectives: Parvovirus B19 (B19V) infection is commonly acute and self-limited, but in chronic kidney disease (CKD) patients under dialysis treatment, this infection could increase susceptibility to acute and chronic anemia. The aim of this study was to evaluate the frequency and risk of B19V infection among Brazilian CKD patients under dialysis. Methods: A study was conducted among 221 CKD patients and a control group of 142 blood donors. B19V infection was evaluated in serum samples by real-time PCR, and ELISA (anti-B19V IgM and IgG). Results: B19V DNA was detected in 65% (145/221) of CKD patients, which was significantly higher (p < 0.001) than in the blood donors (6.3%). Simultaneous detection of B19V IgG and viremia was shown in 40.3% of CKD patients, which was indicative of persistent B19V infection. CKD patients showed an increased risk of developing B19V infection (OR = 28.1, CI = 13.5-58.5, p = 0.001). Conclusions: Despite an absence of clinical signs of B19V infection, these data highlight the importance of B19V infection in this high-risk population, since a persistent B19V infection could become clinically significant after renal transplant. Moreover, the persistent viremia should be considered as a potential risk, mainly because of the contamination of dialysis equipment.

show abstract

“…Based on available reports, genotypes 1 and 3 are present in frequencies of 87.94 and 11.70 per cent, respectively ( Table III ). Some of the studies showed prevalence of both genotype 1 (commonly) and genotype 3 (rarely) 61 65 66 , while other studies showed the prevalence of genotype 1 only 62 64 67 .…”

Section: Geographical Distribution Of Circulating Genotypes In Varioumentioning

confidence: 99%

Genotypes of erythrovirus B19, their geographical distribution & circulation in cases with various clinical manifestations

Jain

Kant

2018

Indian J Med Res

View full text Add to dashboard Cite

Erythrovirus B19 (B19V) is one of the erythroviruses known to be pathogenic in humans. B19V is classified into three distinct genotypes; 1, 2 and 3, differing from each other by 2-13 per cent. Genotype 1 consists of the prototype B19V isolates, genotype 2 comprises the A6, LaLi and their related isolates while genotype 3 includes the V9- and V9-related isolates. The classification of genotype 1 into two subtypes (1A and 1B) and genotype 3 into two subtypes (3a and 3b) with an estimated nucleotide difference of about 5 per cent has been done. Predominance of genotype 1 across all the continents is seen followed by genotypes 2 and 3. There are no disease-specific genotypes. All the three genotypes have been found in symptomatic as well as asymptomatic individuals and have been reported from several countries across the world. The prevalence of genotype 2 in older populations and its absence from current circulation in Northern Europe has also been reported. The present review focuses on geographic distribution and association of genotypes of B19V with different clinical manifestations.

show abstract

Clinical features and laboratory findings of human parvovirus B19 in human immunodeficiency virus-infected patients

Cited by 12 publications

References 27 publications

Frequency and genotype of human parvovirus B19 among Iranian patients infected with HIV

Frequency and genotype of human parvovirus B19 among Iranian patients infected with HIV

High prevalence of parvovirus B19 infection in patients with chronic kidney disease under hemodialysis: A multicenter study

Genotypes of erythrovirus B19, their geographical distribution & circulation in cases with various clinical manifestations

Contact Info

Product

Resources

About